Enhancing APLNR signaling may offer multifaceted benefits, including blood pressure reduction via nitric-oxide-dependent vasodilation [41], improved cardiac contractility—potentially benefiting patients with heart failure with reduced ejection fraction while avoiding the adverse effects of conventional inotropes [36]—and anti-fibrotic effects that could reverse myocardial fibrosis [41]. The gene discussed is APLNR; the disease is heart failure.